Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1094 stories · page 3 of 11
FTSE 100 closes with solid gains, Budget to be 6 March
London index was up fifty points in early dealings but drifted back towards the close
Archive
FTSE 100 Live: Stocks fade after bright start to end little changed
At the close, London's blue-chip index was down 2.12 points at 7,542.77 while the FTSE 250 was down 88.27 points, 0.5%, at 18,662.12
Archive
FTSE 100 Live: Stocks end on a high after ECB says rate hikes are over
London's main index finished the week on a high note
Archive
FIVE at FIVE: AstraZeneca boss denial; $53 billion oil takeover; BT environmental calls; Shoplifting crackdown; FTSE 100 falls
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca settles Nexium heartburn drug cases for US$425m
AstraZeneca denied liability and said it has settled to avoid costly litigation
AstraZeneca bounces back from reports CEO Soriot is eyeing exit
There are a number of potential successors on the board if the news turns out to be true
Barclays starts bank season while UK top dog Astra reports: Thursday agenda
AstraZeneca, Barclays, Currys, London Stock Exchange,Taylor Wimpey, Unilever, WPP and J Sainsbury plus more all report Thursday
Big Pharma earnings bonanza could shape sector going forward: PREVIEW
Eli Lilly and Company, Merck & Co, AstraZeneca PLC, Sanofi and Bristol-Myers Squibb are all expected to report earnings before the bell on Thursday
FIVE at FIVE: AstraZeneca jumps Pfizer, Royal Mail confusion, LVMH soars and Lloyds upgraded
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca earnings per share forecasts raised by Barclays
Barclays raised AstraZeneca's earnings per share forecasts after the biotech company penned a new deal on Tuesday
AstraZeneca premium justified by long-term potential says broker
Pipeline prospects give a 13,000p/share target says Shore Capital
Brexit driving UK manufacturers to turn away from foreign suppliers
40% of UK manufacturers have looked to domesticate supply lines, while many EU firms are complacent about trading with British companies, Make UK says
AstraZeneca to acquire CinCor for US$1.8bn
CinCor's key treatment tackles the effects of diseases such as hypertension, diabetes and vascular defects
AstraZeneca posts mixed results from lung cancer trial
Imfinzi missed its primary endpoint but achieved its secondary result
FIVE at FIVE: UK inflation eases; BT price changes probed by Ofcom; AstraZeneca assessed; Sam Bankman-Fried denied bail
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
AstraZeneca attractive in near term but patent cliffs loom, says broker
AstraZeneca's project pipelines means it has positive near-term prospects, but Jefferies lowered earnings forecasts
AstraZeneca a ‘buy’ for project pipeline potential – broker
Shore reiterated a price target of £127 by the end of 2023, up from almost £114 currently.
AstraZeneca a buy after strong quarter- Shorecap
Shore Capital Group Ltd reiterated its recommendation that AstraZeneca was a buy after strong quarterly results
AstraZeneca raises earnings guidance as profit margins improve
Last year's acquisition of Alexion and a "favourable product mix" had a positive impact
AstraZeneca receives backing for new rescue inhaler
The new product is being developed jointly by AZ and UK group Avillion
AstraZeneca says Beyfortus gets EU approval for respiratory virus in infants
Beyfortus is the first and only single-dose respiratory syncytial virus (RSV) passive immunisation for the broad infant population
AstraZeneca shares will get lift from heartburn drug litigation closure, says Citi
The UK pharma is one of several firms embroiled in US legal action over possible kidney damage
AstraZeneca trial of Fasrena fails to help with eosinophilic esophagitis swallowing problems
Eosinophilic esophagitis is a rare, progressive, chronic inflammatory disease of the oesophagus, which can lead to difficulty with swallowing, pain, food getting stuck and anxiety